News

Sema4 to Deliver High Capacity COVID-19 Testing in Partnership with the State of Connecticut

Sema4 has announced a formal partnership with the State of Connecticut to be a COVID-19 testing provider for Connecticut residents. Sema4 will provide viral and antibody testing, along with an end-to-end digital solution.


READ MORE

Notable Financial and Technology Executive R. Martin Chavez Joins Sema4 Board of Directors

Sema4 announced that R. Martin Chavez, a prominent Wall Street and technology executive, has joined its Board of Directors.


READ MORE

Sema4 Named a Cool Vendor by Gartner in the April 2020 Cool Vendors in Healthcare Technology Report

Sema4 announced that it has been named a 2020 Cool Vendor in Healthcare Technology by Gartner Inc., the world’s leading research and advisory company.


READ MORE

Sema4 Launches High-Capacity COVID-19 Testing to Address Critical Need Across Connecticut and New York

Sema4 announced that it is now performing rapid molecular testing for the detection of SARS-CoV-2, the coronavirus responsible for COVID-19.


READ MORE
SEMA4 PRESS RELEASE | 03.12.20

Former Senior FDA Official Dr. Rachel Sherman Joins Sema4 Board of Directors

Sema4 announced the appointment of Rachel Sherman, MD, MPH, to its Board of Directors. Dr. Sherman is the former Principal Deputy Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA).


READ MORE
CLINICAL OMICS | 03.03.20

Sema4, VieCure Launch Precision Oncology Collaboration

Clinical OMICs published an article covering Sema4’s strategic alliance with VieCure. The piece covers how the collaboration between the two companies is accelerating precision oncology care.


READ MORE
SEMA4 PRESS RELEASE | 03.02.20

Sema4 and VieCure Announce Strategic Collaboration to Accelerate Precision Oncology Care

Sema4, a patient-centered health intelligence company, and VieCure, an artificial intelligence (AI) informatics company with a leading point-of-care clinical decision support platform and a comprehensive electronic medical record (EMR) in oncology, today announced a strategic collaboration designed to help oncologists deliver personalized care and treatment to their patients.
READ MORE
Governor’s Innovation Fellowship in Connecticut | 02.24.20

Sema4 Participates in Governor’s Innovation Fellowship

Sema4 is one of nine companies participating in the Governor’s Innovation Fellowship in Connecticut. The office of Connecticut Governor Ned Lamont issued a press release on the Fellowship, a pilot program enabling college graduates to start their careers with a job at select growing companies, including Sema4. The announcement referenced Sema4 as “the fastest-growing health intelligence company in the country.”
READ MORE
CLINICAL OMICS | 02.11.20

Moving the Diagnostics Needle for Personalized Care

Clinical OMICs featured comments that Eric Schadt, Ph.D., Founder and CEO of Sema4, made in a recent panel discussion titled “Transformative Technologies: Previewing the Value Proposition and Outlook for Disruptive Tools Designed to Enable Personalized Medicine.” The panel was chaired and moderated by Michael Pellini, M.D., a member of Sema4’s Board of Directors. At Sema4, “the focus is on developing actionable data from patients, while also keeping the patient in control of their own health data,” shared Eric. Read the full article below by Chris Anderson, Editor-in-Chief at Clinical Omics.
READ MORE
SEMA4 PRESS RELEASE | 11.14.19

Sema4 Appoints Biotech Leader Joel Sendek as Chief Financial Officer

Sema4 announces the appointment of Joel Sendek as Chief Financial Officer. Mr. Sendek has more than 25 years of financial leadership experience in the pharmaceutical and biotechnology sector, including overseeing the successful initial public offerings at his last two companies.
READ MORE